Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 3:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 33,591 matching trials from the live ClinicalTrials.gov search.
Conditions
Batten Disease
Interventions
Miglustat 100 milligrams (mg) Oral Capsule
Drug
Lead sponsor
Beyond Batten Disease Foundation
Other
Eligibility
17 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Conditions
Migraine Disorders
Interventions
Qudexy XR, Placebo
Drug
Lead sponsor
Upsher-Smith Laboratories
Industry
Eligibility
6 Years to 11 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
15
States / cities
Birmingham, Alabama • La Jolla, California • Aurora, Colorado + 12 more
Conditions
Gastric Cancer, Hepatocellular Carcinoma
Interventions
Telatinib, Keytruda
Drug
Lead sponsor
Andrew Hendifar, MD
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Beverly Hills, California • Los Angeles, California
Conditions
Benign Prostatic Hyperplasia
Interventions
tadalafil, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
1,058 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Greenwood, Indiana
Conditions
Intraocular Lens Replacement
Interventions
OMS302, Placebo
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Chandler, Arizona • Los Angeles, California • Fort Myers, Florida + 10 more
Conditions
Mast Cell Activation Syndrome, Mast Cell Activation Disorder Idiopathic
Interventions
FSD201, Placebo
Drug
Lead sponsor
Quantum Biopharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
2
States / cities
Weldon Spring, Missouri • New York, New York
Completed Phase 2 Interventional Accepts healthy volunteers Results available

2013/2017 H7N9 Prime-Boost Interval

NCT03589807
Conditions
Avian Influenza, Influenza Immunisation
Interventions
A/H7N9, AS03, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, Phosphate Buffered Saline (PBS) diluent
Biological · Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 50 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
6
States / cities
Atlanta, Georgia • Decatur, Georgia • Iowa City, Iowa + 3 more
Conditions
Optic Neuritis
Interventions
Clemastine, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
San Francisco, California
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Clarithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland
Conditions
Obesity and Overweight
Interventions
NA-931, Tirzepatide, NA-931 150 mg + no Tirzepatide
Drug
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
19 Years to 80 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 5 more
Conditions
Locally Advanced or Metastatic Pancreatic Cancer
Interventions
FG-3019
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
7
States / cities
Stanford, California • Lebanon, New Hampshire • Cleveland, Ohio + 4 more
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Contraceptive Effectiveness and Safety of the SILCS Diaphragm

NCT00578877
Conditions
Contraception
Interventions
SILCS Diaphragm, Nonoxynol-9 Gel, Buffer Gel
Device · Combination Product
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 40 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • Philadelphia, Pennsylvania + 3 more
Not listed Not applicable Interventional Accepts healthy volunteers

A Sub-Chronic Evaluation of the Safety of Celastrol in Human Subjects

NCT05494112
Conditions
Safety
Interventions
Celastrol
Dietary Supplement
Lead sponsor
Legend Labz, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
Andecaliximab, Nivolumab
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 3 more
Conditions
Healthy, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis
Interventions
PF-06817024, Placebo for PF-06817024
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
20
States / cities
Sacramento, California • New Haven, Connecticut • Shelton, Connecticut + 12 more
Conditions
Primary Sjögren Syndrome, Dry Eye
Interventions
0.005% Lacripep, 0.01% Lacripep, Placebo
Drug
Lead sponsor
TearSolutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Azusa, California + 31 more
Conditions
Spondylolisthesis, Scoliosis, Intervertebral Disc Disease
Interventions
OsteoAMP
Other
Lead sponsor
Bioventus LLC
Industry
Eligibility
21 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
9
States / cities
New Haven, Connecticut • Chicago, Illinois • Kansas City, Kansas + 6 more
Conditions
Candidiasis, Candidemia
Interventions
voriconazole (Vfend)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 11 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
14
States / cities
Tucson, Arizona • Orange, California • Jacksonville, Florida + 8 more
Conditions
Skin Ageing, Facial Wrinkles, Acne, Skin Elasticity, Infraorbital Dark Circle Severity, Skin Firmness, UV Spots, Skin Texture, Skin Pores, Brown Spots, Porphyrins, Red Spots
Interventions
NIRA Laser M2.1, Topical
Device · Other
Lead sponsor
NIRA Innovations Inc.
Industry
Eligibility
35 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Beverly, Massachusetts
Conditions
Prostate Cancer
Interventions
dMD-002, Control
Device · Other
Lead sponsor
Mochida Medical USA, Inc.
Industry
Eligibility
40 Years to 74 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Accepts healthy volunteers

Non-Invasive Blood Test Cross-Validation Study

NCT03991637
Conditions
Reproducibility of Results, Safety Issues
Interventions
Non-Invasive Comprehensive Metabolic Panel
Device
Lead sponsor
Joseph Allen Jr.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Grand Forks, North Dakota
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Dantrolene in Subarachnoid Hemorrhage

NCT01024972
Conditions
Subarachnoid Hemorrhage, Cerebral Vasospasm
Interventions
Dantrolene, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Healthy Participants
Interventions
AZD2389, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Glendale, California
Conditions
Upper Limb Spasticity
Interventions
Botulinum toxin type A, BoNT-A, Rehabilitation Therapy
Drug · Other
Lead sponsor
JoAnn Harnar
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Albuquerque, New Mexico